Psychology - Today
Manchester experts to help robots better understand human emotions and improve dialogue with machines
Manchester experts to help robots better understand human emotions and improve dialogue with machines
Life Sciences - Today
UCL professors win European Research Council grants to explore cutting-edge research
UCL professors win European Research Council grants to explore cutting-edge research
Research management - Today
University of Glasgow researchers share in ¤544m ERC Advanced Grant funding
University of Glasgow researchers share in ¤544m ERC Advanced Grant funding
wire
« BACK
Health - Pharmacology - 27.06.2022 
Interrupting the treatment of vulnerable people on immune-suppressing medicines, doubles their antibody response to COVID-19 booster vaccination
A major clinical trial, led by experts at the University of Nottingham working in partnership with Universities and NHS hospitals including the University of Manchester , has found that by interrupting the treatment of vulnerable people on long-term immune suppressing medicines for two weeks after a COVID-19 booster vaccination, their antibody response to the jab is doubled.
Pharmacology - Health - 24.06.2022
Health - Pharmacology - 22.06.2022 
COPD patients respond equally well to COVID-19 vaccine
A study which tested the immune response of COPD patients to COVID-19 vaccination has shown they respond in a similar way to healthy people.
Pharmacology - 21.06.2022
Health - Pharmacology - 17.06.2022
Health - Pharmacology - 16.06.2022
Health - Pharmacology - 16.06.2022
Pharmacology - Health - 15.06.2022 
UK researchers pioneer new virtual treatment for PTSD
Researchers at Cardiff University have pioneered a new form of virtual treatment for people with post-traumatic stress disorder (PTSD).
Pharmacology - 07.06.2022 
COVID-19 and Brexit ’caused sharp rise in copycat ecstasy’
A new study has highlighted the apparent effect of Brexit and the pandemic on the trade in the illegal party drug ecstasy (MDMA). Researchers from The Loop, a UK drug checking charity, found almost half (45%) of substances sold as MDMA at English festivals last year contained none - and instead contained other drugs such as caffeine or cathinones.
Pharmacology - Health - 06.06.2022
Pharmacology - Health - 26.05.2022
Pharmacology - Health - 25.05.2022 
University spinout in major partnership to commercialize treatment for invasive aspergillosis
F2G, a University of Manchester spinout company, is to partner a major Japanese pharmaceutical company in the commercialisation of a novel antifungal treatment it developed for invasive aspergillosis and other rare mould infections.
Health - Pharmacology - 15.05.2022 
Robotic surgery is safer and improves patient recovery time
Robot-assisted surgery used to perform bladder cancer removal enables patients to recover far more quickly and spend significantly (20 per cent) less time in hospital, concludes a first-of-its kind clinical trial led by scientists at UCL and the University of Sheffield.
Pharmacology - Health - 12.05.2022
Health - Pharmacology - 12.05.2022 
New report outlines vision for safe, effective and accessible medicines in pregnancy
A UK-first report into the state of pregnancy medicine, which was co-commissioned by Professor Anna David (UCL EGA Institute for Women's Health), has proposed a clear roadmap to help reduce the high number of needless newborn deaths and improve maternal health.
Pharmacology - 11.05.2022
Health - Pharmacology - 04.05.2022 
Guidance on living safely with infections
The Government has removed the remaining domestic COVID-19 restrictions in England - find out about our updated advice for living safely with respiratory infections including COVID-19.
Health - Pharmacology - 26.04.2022
Health - Pharmacology - 04.04.2022 
Major new investment in clinical research at UCL
Pioneering clinical research carried out at UCL will benefit from almost £12m in new funding, thanks to a major investment by University College London Hospitals NHS Foundation Trust (ULCH).
Health - Pharmacology - 31.03.2022
Health - Pharmacology - 21.03.2022
Pharmacology - Health - 19.03.2022
Health - Pharmacology - 28.02.2022
Pharmacology - 23.02.2022
Health - Pharmacology - 23.02.2022 
Vitamin B3 trialled as glaucoma treatment
A major four-year clinical trial to test the effectiveness of nicotinamide (NAM), a form of vitamin B3, as a treatment for glaucoma is to be led by UCL and Moorfields Eye Hospital researchers.
Health - Pharmacology - 23.02.2022
Health - Pharmacology - 18.02.2022
Health - Pharmacology - 14.02.2022
Health - Pharmacology - 10.02.2022 
Engineering quality of life for people with advanced cancers
A major £7 million research collaboration between UCL, the University of Leeds and Imperial College London has been launched to develop a new imaging and keyhole surgery approach to treating secondary bone tumours of the spine.
Health - Pharmacology - 09.02.2022
Health - Pharmacology - 08.02.2022 
Covid safe? It’s our ancestors we should be thanking
We owe a vote of thanks to our ancestors for inventing some of the most important measures to keep us safe during the Covid 19 pandemic, argues a University of Manchester scientist in a new book.
Health - Pharmacology - 04.02.2022
Health - Pharmacology - 31.01.2022 
Opinion: Could probiotics help fight off Covid-19?
Probiotics are added to food with the aim of benefitting gut health, however research also suggests they may benefit our immune system and could even help fight Covid-19.
Pharmacology - Life Sciences - 27.01.2022 
Collaborative research approach set to accelerate treatment of rare kidney condition
Partnership with Kidney Research UK and a £2.55 million investment from the Stoneygate Trust aims to deliver a world leading research programme Using patient data along with a new platform of technologies to test new treatments such as gene therapy, researchers aim to deliver major results within five years' time A new research programme dedicated to the study and treatment of Alport syndrome will begin work in early 2022, with a physical hub based at the University of Manchester.
Health - Pharmacology - 27.01.2022
Health - Pharmacology - 26.01.2022 
Volunteers needed for human challenge trial to study immune response to Covid-19
Oxford researchers are seeking participants for a trial to discover what happens when people who have either already had Covid-19 or who have been vaccinated are exposed to the original strain of virus. Researchers at the University of Oxford are looking for volunteers to take part in a human challenge trial to look at what kind of immune response can stop people from becoming infected with the original strain of the virus.
Health - Pharmacology - 26.01.2022
Pharmacology - Health - 20.01.2022
Pharmacology - Health - 17.01.2022
Health - Pharmacology - 17.01.2022
Pharmacology - Health - 17.01.2022 
UCL startup acquired by biotechnology company in bid to find cancer drugs in ’record time’
Machine learning company, Rahko, has been bought by US-based biotechnology firm, Odyssey Therapeutics, in a move that will bring together artificial intelligence and drug-discovery software to improve medical development for patients with cancer and inflammatory diseases.
Health - Pharmacology - 13.01.2022
Health - Pharmacology - 13.01.2022 
COVID: why T cell vaccines could be the key to long-term immunity
With omicron having rapidly driven up COVID infections, attention is once again focusing on antibodies, and reasonably so.
Pharmacology - Health - 08.01.2022
Health - Pharmacology - 04.01.2022 
Early data for multivariant COVID-19 vaccine booster shows promise
The first results of an early trial of a multivariant COVID-19 vaccine booster, launched in Manchester in September 2021, has shown it is driving a comprehensive immune response.
Health - Pharmacology - 21.12.2021
Health - Pharmacology - 21.12.2021 
Cancer researchers across the UK join forces to find drugs for rare cancers
Cancer Research UK, The University of Manchester and Roche, today (Monday 20th), announce a partnership to run a multi-drug, precision medicine platform trial for adults and children with rare cancers who have run out of other treatment options.
Health - Pharmacology - 20.12.2021
Health - Pharmacology - 20.12.2021 
Covid-19 vaccine protection wanes after three months
Covid-19 vaccine protection wanes after three months, study suggests The protection offered by the Oxford-Astra Zeneca Covid-19 vaccine declines after three months of receiving two doses, a study says. The findings - drawn from datasets in two countries - suggest that booster programmes are needed to help maintain protection from severe disease in those vaccinated with Oxford-Astra Zeneca, experts say.
Pharmacology - Health - 15.12.2021 
TaBriX, University and TB Alliance to develop drug-resistant tuberculosis treatments
TaBriX is a new spin-out company from The University of Manchester (UoM) with the mission to create novel anti-virulence drugs to fight difficult-to-treat infections.
Pharmacology
Results 51 - 100 of 586.
A major clinical trial, led by experts at the University of Nottingham working in partnership with Universities and NHS hospitals including the University of Manchester , has found that by interrupting the treatment of vulnerable people on long-term immune suppressing medicines for two weeks after a COVID-19 booster vaccination, their antibody response to the jab is doubled.
Which patients with advanced prostate cancer will benefit from chemotherapy
Researchers have recommended changes to how cancer patients are treated, after a new UCL-led study discovered that chemotherapy is significantly more effective for some men with advanced prostate cancer than others.
Researchers have recommended changes to how cancer patients are treated, after a new UCL-led study discovered that chemotherapy is significantly more effective for some men with advanced prostate cancer than others.
A study which tested the immune response of COPD patients to COVID-19 vaccination has shown they respond in a similar way to healthy people.
Heart surgery delays will cost lives, warns research
Pandemic has delayed lifesaving treatment for thousands of people with severe aortic stenosis. Our approach does not put the onus on only management or doctors, but creates a joint solution that is easier to implement in practice Feryal Erhun Urgent action is needed to clear the backlog of people with a common heart condition who are waiting for lifesaving treatment, according to published in the journal BMJ Open .
Pandemic has delayed lifesaving treatment for thousands of people with severe aortic stenosis. Our approach does not put the onus on only management or doctors, but creates a joint solution that is easier to implement in practice Feryal Erhun Urgent action is needed to clear the backlog of people with a common heart condition who are waiting for lifesaving treatment, according to published in the journal BMJ Open .
New system that defines Huntington’s Disease will ’revolutionise’ drug trials
A novel staging framework that assesses the progression of Huntington's disease (HD), similar to the way cancer is staged 0 to 4, has been developed by UCL scientists as part of an international consortium; paving the way for clinical trials of drugs in the earliest stages of HD.
A novel staging framework that assesses the progression of Huntington's disease (HD), similar to the way cancer is staged 0 to 4, has been developed by UCL scientists as part of an international consortium; paving the way for clinical trials of drugs in the earliest stages of HD.
Researchers in Glasgow to receive £1.9m to tackle late stage cancer syndrome
Scientists at the Cancer Research UK Beatson Institute and the University of Glasgow are to receive £1.9m to explore the causes of a debilitating wasting disease that many people experience in the later stages of cancer. The funding is from Cancer Grand Challenges, a research initiative co-founded by Cancer Research UK and the National Cancer Institute in the US, which aims to encourage the world's leading researchers to tackle the toughest challenges faced by cancer patients.
Scientists at the Cancer Research UK Beatson Institute and the University of Glasgow are to receive £1.9m to explore the causes of a debilitating wasting disease that many people experience in the later stages of cancer. The funding is from Cancer Grand Challenges, a research initiative co-founded by Cancer Research UK and the National Cancer Institute in the US, which aims to encourage the world's leading researchers to tackle the toughest challenges faced by cancer patients.
Researchers at Cardiff University have pioneered a new form of virtual treatment for people with post-traumatic stress disorder (PTSD).
A new study has highlighted the apparent effect of Brexit and the pandemic on the trade in the illegal party drug ecstasy (MDMA). Researchers from The Loop, a UK drug checking charity, found almost half (45%) of substances sold as MDMA at English festivals last year contained none - and instead contained other drugs such as caffeine or cathinones.
Study identifies best treatment for rare childhood cancer
High doses of drug called ifosfamide are the best way to treat a cancer of children which affects bones and soft tissues, compared to three other treatments, according to University of Manchester researchers.
High doses of drug called ifosfamide are the best way to treat a cancer of children which affects bones and soft tissues, compared to three other treatments, according to University of Manchester researchers.
F2G, a University of Manchester spinout company, is to partner a major Japanese pharmaceutical company in the commercialisation of a novel antifungal treatment it developed for invasive aspergillosis and other rare mould infections.
Robot-assisted surgery used to perform bladder cancer removal enables patients to recover far more quickly and spend significantly (20 per cent) less time in hospital, concludes a first-of-its kind clinical trial led by scientists at UCL and the University of Sheffield.
Spotlight on... Professor Jayant S Vaidya
This week Jayant, Professor of Surgery and Oncology at UCL Division of Surgery, shares the story of how he helped to develop a pioneering new treatment for breast cancer, which is featured as a case study in UCL's latest REF submission.
This week Jayant, Professor of Surgery and Oncology at UCL Division of Surgery, shares the story of how he helped to develop a pioneering new treatment for breast cancer, which is featured as a case study in UCL's latest REF submission.
A UK-first report into the state of pregnancy medicine, which was co-commissioned by Professor Anna David (UCL EGA Institute for Women's Health), has proposed a clear roadmap to help reduce the high number of needless newborn deaths and improve maternal health.
The Government has removed the remaining domestic COVID-19 restrictions in England - find out about our updated advice for living safely with respiratory infections including COVID-19.
Pioneering clinical research carried out at UCL will benefit from almost £12m in new funding, thanks to a major investment by University College London Hospitals NHS Foundation Trust (ULCH).
New ovarian cancer study to determine mechanism behind treatment resistance
A new research project led by the Univerity of Glasgow and funded by leading health charity Wellbeing of Women, in partnership with Artios Pharma Limited (Artios), will investigate why some advanced ovarian cancers become resistant to a new type of treatment called PARP inhibitors.
A new research project led by the Univerity of Glasgow and funded by leading health charity Wellbeing of Women, in partnership with Artios Pharma Limited (Artios), will investigate why some advanced ovarian cancers become resistant to a new type of treatment called PARP inhibitors.
Scientists use vaccination to successfully treat COVID-19 for first time
Doctors have successfully used vaccination to treat a patient with COVID-19 in what is thought to be the first instance of the vaccine being used for therapy instead of prevention.
Doctors have successfully used vaccination to treat a patient with COVID-19 in what is thought to be the first instance of the vaccine being used for therapy instead of prevention.
A major four-year clinical trial to test the effectiveness of nicotinamide (NAM), a form of vitamin B3, as a treatment for glaucoma is to be led by UCL and Moorfields Eye Hospital researchers.
New guidelines for endometriosis set to help millions of women with chronic condition
Scientists from UCL and UCLH have informed a new set of clinical guidelines to aid better diagnosis and management of endometriosis - a chronic condition that causes severe pelvic pain and reduced fertility for millions of women worldwide.
Scientists from UCL and UCLH have informed a new set of clinical guidelines to aid better diagnosis and management of endometriosis - a chronic condition that causes severe pelvic pain and reduced fertility for millions of women worldwide.
Global study launched to evaluate effects of Covid-19 variants and vaccination in pregnancy
INTERCOVID-2022: The University of Oxford is to launch the 2022 round of the global study to evaluate the effects of Covid-19 variants and vaccination in pregnancy.
INTERCOVID-2022: The University of Oxford is to launch the 2022 round of the global study to evaluate the effects of Covid-19 variants and vaccination in pregnancy.
A major £7 million research collaboration between UCL, the University of Leeds and Imperial College London has been launched to develop a new imaging and keyhole surgery approach to treating secondary bone tumours of the spine.
Diabetes drugs could save thousands of lives
Stock-photo-closeup-of-a-young-caucasian-man-with-a-blue-circle-symbol-of-the-diabetes-in-his-forefinger-in-1223612143.jpg closeup of a young caucasian man with a blue circle, symbol of the diabetes, in his forefinger, in support of this disease New research has linked two types of less-often prescribed diabetes drugs with lower chances of potentially fatal heart problems - including heart attack, heart failure and stroke - in people with type 2 diabetes without established heart disease.
Stock-photo-closeup-of-a-young-caucasian-man-with-a-blue-circle-symbol-of-the-diabetes-in-his-forefinger-in-1223612143.jpg closeup of a young caucasian man with a blue circle, symbol of the diabetes, in his forefinger, in support of this disease New research has linked two types of less-often prescribed diabetes drugs with lower chances of potentially fatal heart problems - including heart attack, heart failure and stroke - in people with type 2 diabetes without established heart disease.
We owe a vote of thanks to our ancestors for inventing some of the most important measures to keep us safe during the Covid 19 pandemic, argues a University of Manchester scientist in a new book.
Research collaboration launched to focus on repurposing existing anti-viral therapies to treat COVID-19
A new £1.6m collaborative project has been launched to rapidly identify new treatments for COVID-19. The project, led by Queen's University Belfast and funded by the Medical Research Council, will bring together experts from Queen's, the University of Liverpool and the University of Oxford. The team will use a data-driven approach to identify novel drug combinations that are effective in tackling SARS-CoV-2, the causative agent of COVID-19.
A new £1.6m collaborative project has been launched to rapidly identify new treatments for COVID-19. The project, led by Queen's University Belfast and funded by the Medical Research Council, will bring together experts from Queen's, the University of Liverpool and the University of Oxford. The team will use a data-driven approach to identify novel drug combinations that are effective in tackling SARS-CoV-2, the causative agent of COVID-19.
Probiotics are added to food with the aim of benefitting gut health, however research also suggests they may benefit our immune system and could even help fight Covid-19.
Partnership with Kidney Research UK and a £2.55 million investment from the Stoneygate Trust aims to deliver a world leading research programme Using patient data along with a new platform of technologies to test new treatments such as gene therapy, researchers aim to deliver major results within five years' time A new research programme dedicated to the study and treatment of Alport syndrome will begin work in early 2022, with a physical hub based at the University of Manchester.
Oxford researchers are seeking participants for a trial to discover what happens when people who have either already had Covid-19 or who have been vaccinated are exposed to the original strain of virus. Researchers at the University of Oxford are looking for volunteers to take part in a human challenge trial to look at what kind of immune response can stop people from becoming infected with the original strain of the virus.
Trial of wearable health technology for cancer patients opens
A new trial opens in Greater Manchester today which is to test cutting-edge wearable technologies involving patients who have received cancer treatment. The commercially-available health sensors and devices produce a digital fingerprint of vital signs that could allow doctors to assess the progress of their patients.
A new trial opens in Greater Manchester today which is to test cutting-edge wearable technologies involving patients who have received cancer treatment. The commercially-available health sensors and devices produce a digital fingerprint of vital signs that could allow doctors to assess the progress of their patients.
Lack of trust in public figures linked to COVID vaccine hesitancy says new research
New research says lack of trust in public sector officials has played a key role in low uptake of COVID-19 vaccinations amongst groups termed "high risk." According to research from the Universities of Birmingham and Leeds, vaccine hesitancy was greatest among people from lower socio-economic and/or ethnic minority backgrounds.
New research says lack of trust in public sector officials has played a key role in low uptake of COVID-19 vaccinations amongst groups termed "high risk." According to research from the Universities of Birmingham and Leeds, vaccine hesitancy was greatest among people from lower socio-economic and/or ethnic minority backgrounds.
Pressure leads GPs to increase antibiotic prescribing
The pressure GPs are working under has been linked to increasing broad-spectrum antibiotic prescribing in England by health economists at The University of Manchester and University of Southern Denmark.
The pressure GPs are working under has been linked to increasing broad-spectrum antibiotic prescribing in England by health economists at The University of Manchester and University of Southern Denmark.
Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy for respiratory virus infections from the University of Warwick
Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has in-licenced a novel, first-in-class RNA-based immunotherapy for respiratory virus infections developed at the.
Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has in-licenced a novel, first-in-class RNA-based immunotherapy for respiratory virus infections developed at the.
Machine learning company, Rahko, has been bought by US-based biotechnology firm, Odyssey Therapeutics, in a move that will bring together artificial intelligence and drug-discovery software to improve medical development for patients with cancer and inflammatory diseases.
Dramatic fall in hospital admissions for child infections since start of covid-19 pandemic
Since the onset of the covid-19 pandemic, there have been dramatic reductions in hospital admissions for common and severe childhood infections in England, most likely due to social distancing measur
Since the onset of the covid-19 pandemic, there have been dramatic reductions in hospital admissions for common and severe childhood infections in England, most likely due to social distancing measur
With omicron having rapidly driven up COVID infections, attention is once again focusing on antibodies, and reasonably so.
Second generation CAR T-cell therapy trialled in patients
A new CAR T-cell therapy developed by scientists at UCL has fewer 'toxic' side-effects and is more durable, targeting and killing cancer cells for longer, concludes a Phase I clinical trial of patients at University College London Hospitals (UCLH).
A new CAR T-cell therapy developed by scientists at UCL has fewer 'toxic' side-effects and is more durable, targeting and killing cancer cells for longer, concludes a Phase I clinical trial of patients at University College London Hospitals (UCLH).
The first results of an early trial of a multivariant COVID-19 vaccine booster, launched in Manchester in September 2021, has shown it is driving a comprehensive immune response.
Cancer Research UK, The University of Manchester and Roche, today (Monday 20th), announce a partnership to run a multi-drug, precision medicine platform trial for adults and children with rare cancers who have run out of other treatment options.
Omicron may be significantly better at evading vaccine-induced immunity, but less likely to cause severe disease
The Omicron variant of SARS-CoV-2 may be significantly better than previous variants at evading vaccine-induced antibodies, according to new research from Cambridge - but preliminary evidence suggests it is less likely to cause severe COVID-19 illness in the lungs. Omicron's mutations present the virus with a double-edged sword: it's got better at evading the immune system, but it might have lost some of its ability to cause severe disease Ravi Gupta As the SARS-CoV-2 virus replicates and spreads, errors in its genetic code can lead to changes in the virus.
The Omicron variant of SARS-CoV-2 may be significantly better than previous variants at evading vaccine-induced antibodies, according to new research from Cambridge - but preliminary evidence suggests it is less likely to cause severe COVID-19 illness in the lungs. Omicron's mutations present the virus with a double-edged sword: it's got better at evading the immune system, but it might have lost some of its ability to cause severe disease Ravi Gupta As the SARS-CoV-2 virus replicates and spreads, errors in its genetic code can lead to changes in the virus.
Covid-19 vaccine protection wanes after three months, study suggests The protection offered by the Oxford-Astra Zeneca Covid-19 vaccine declines after three months of receiving two doses, a study says. The findings - drawn from datasets in two countries - suggest that booster programmes are needed to help maintain protection from severe disease in those vaccinated with Oxford-Astra Zeneca, experts say.
TaBriX is a new spin-out company from The University of Manchester (UoM) with the mission to create novel anti-virulence drugs to fight difficult-to-treat infections.
Psychology - Today
Manchester experts to help robots better understand human emotions and improve dialogue with machines
Manchester experts to help robots better understand human emotions and improve dialogue with machines
Life Sciences - Today
UCL professors win European Research Council grants to explore cutting-edge research
UCL professors win European Research Council grants to explore cutting-edge research
Research management - Today
University of Glasgow researchers share in ¤544m ERC Advanced Grant funding
University of Glasgow researchers share in ¤544m ERC Advanced Grant funding